Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis - PubMed (original) (raw)

Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis

Elke Ueberham et al. Hepatology. 2003 May.

Abstract

Based on the tetracycline-regulated gene expression system, a double-transgenic mouse model for liver fibrosis was established in which the expression of transforming growth factor beta1 (TGF-beta1) can be regulated deliberately by addition or removal of doxycycline hydrochloride to the drinking water. TGF-beta1 plasma levels in induced double-transgenic mice reached values ranging from 250 to 1,200 ng/mL, being 10 to 30 times above the normal plasma levels. By applying a cyclic induction-deinduction protocol, deleterious effects of the high plasma TGF-beta1 levels were overcome. By using this protocol, liver fibrosis occurred within a few cycles and progressed further to an intermediary fibrosis when cyclic induction was continued. On histochemical staining, a marked perisinusoidal deposition of extracellular matrix was detected accompanied by the activation of hepatic stellate cells as shown by alpha-smooth muscle actin (alpha-SMA) expression. Apoptosis of hepatocytes was prominent in TGF-beta1 high producers, leading to a decreasing number of TGF-beta1-expressing cells with time. No compensatory proliferation of hepatocytes could be detected. In advanced stages, fibrogenesis could be stopped by switching off TGF-beta1 production and reversal of fibrosis could be shown by (immuno)histochemistry within 6 to 21 days. Determination of messenger RNA (mRNA) levels of procollagen I and III, laminin (B1), matrix metalloproteinase (MMP)-2, -9, and -13, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 and -2 by real-time reverse-transcription polymerase chain reaction (RT-PCR) provided insight into some mechanistic details of the fibrogenic process and its reversal. In conclusion, this model will enable the analysis of fibrogenesis at progressive stages and help in elucidating the cellular changes during development and regression of liver fibrosis caused by elevated TGF-beta1 expression.

PubMed Disclaimer

Similar articles

• Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
  Xu W, Wang LW, Shi JZ, Gong ZJ. Xu W, et al. Hepatobiliary Pancreat Dis Int. 2009 Jun;8(3):300-8. Hepatobiliary Pancreat Dis Int. 2009. PMID: 19502172
• Reduction and expansion of the glutamine synthetase expressing zone in livers from tetracycline controlled TGF-beta1 transgenic mice and multiple starved mice.
  Ueberham E, Arendt E, Starke M, Bittner R, Gebhardt R. Ueberham E, et al. J Hepatol. 2004 Jul;41(1):75-81. doi: 10.1016/j.jhep.2004.03.024. J Hepatol. 2004. PMID: 15246211
• Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.
  Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW, Kanzler S. Czochra P, et al. J Hepatol. 2006 Sep;45(3):419-28. doi: 10.1016/j.jhep.2006.04.010. Epub 2006 May 30. J Hepatol. 2006. PMID: 16842882
• Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis.
  Liu X, Hu H, Yin JQ. Liu X, et al. Liver Int. 2006 Feb;26(1):8-22. doi: 10.1111/j.1478-3231.2005.01192.x. Liver Int. 2006. PMID: 16420505 Review.

Cited by

• Cell signals influencing hepatic fibrosis.
  Cong M, Iwaisako K, Jiang C, Kisseleva T. Cong M, et al. Int J Hepatol. 2012;2012:158547. doi: 10.1155/2012/158547. Epub 2012 Aug 29. Int J Hepatol. 2012. PMID: 22973518 Free PMC article.
• Metabolic Profile Changes of CCl₄-Liver Fibrosis and Inhibitory Effects of Jiaqi Ganxian Granule.
  Wang G, Li Z, Li H, Li L, Li J, Yu C. Wang G, et al. Molecules. 2016 May 30;21(6):698. doi: 10.3390/molecules21060698. Molecules. 2016. PMID: 27248993 Free PMC article.
• Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells.
  Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, Glick AB, Hähnel B, Hosser H, Gröne HJ, Kriz W. Koesters R, et al. Am J Pathol. 2010 Aug;177(2):632-43. doi: 10.2353/ajpath.2010.091012. Epub 2010 Jul 8. Am J Pathol. 2010. PMID: 20616344 Free PMC article.
• TGF-β in progression of liver disease.
  Dooley S, ten Dijke P. Dooley S, et al. Cell Tissue Res. 2012 Jan;347(1):245-56. doi: 10.1007/s00441-011-1246-y. Epub 2011 Oct 19. Cell Tissue Res. 2012. PMID: 22006249 Free PMC article. Review.
• Smad2 protects against TGF-β1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis.
  Zhang L, Liu C, Meng XM, Huang C, Xu F, Li J. Zhang L, et al. Mol Cell Biochem. 2015 Feb;400(1-2):17-28. doi: 10.1007/s11010-014-2258-1. Epub 2014 Oct 29. Mol Cell Biochem. 2015. PMID: 25351340

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal